Gastric Acid-Suppressants Exacerbates Dementia Risk Among Patients with Gastrointestinal Disease, Study Finds

A recent study has discovered that use of gastric acid-suppressive agents, such as proton pump inhibitors (PPI) and histamine type-2 receptor antagonists (H2Ras) may exacerbate the risk of dementia among patients with upper gastrointestinal diseases (UGID).

Photo: Gastrointestinal Problem | InStyleHealth


Utilizing the 2000 – 2015 data from the National Longitudinal Health Insurance Database, the researchers performed a retrospective cohort study on 6,711 UGID patients who were on gastric acid-suppressive agents. The result of interest was dementia, and its incidence was compared against 6,711 UGID patients without such medication, and 6,711 controls without UGID or treatment.

Throughout 10 years of follow-up, 457 UGID patients on gastric acid-suppressive medications developed dementia, generating an incidence rate of 6.81%. In contrast, the incidence rate was 4.46% among patients not on such medication, and 3.64% among the control group.

Using the cox proportional hazard analysis discovered that UGID patients taking suppressive medications were nearly 50% more likely to have dementia than comparators not on similar medications. The analysis was adjusted for age, gender, comorbidities, and other medications.

Particularly, there was no such effect was detected when the non-medicated UGID patients were compared with the control group.

Classifying according to the type of agent taken showed that proton pump inhibitors PPIs had a stronger effect on H2Ras. Especially, PPI use was even a significantly greater risk factor for dementia than H2Ras.

For complete details of this clinical study, click here.

 

Source: PLoS One 2021;doi:10.1371/journal.pone.0249050

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post